

12 Jun 2022 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: paradigm-shifting breast cancer and KRAS inhibitor results at ASCO; BMS' targeted oncology acquisition; a snapshot of the multiple sclerosis market; and a look at Aduhelm one year later.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 10 June 2022, including: paradigm-shifting breast cancer and KRAS inhibitor results at ASCO; BMS' targeted oncology acquisition; a snapshot of the MS market; and a look at Aduhelm one year later.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[ASCO: AstraZeneca's Enhertu Is Poised To Change The Breast Cancer Paradigm](#)" - Scrip, 5 Jun, 2022.)

(Also see "[Mirati Seeks Differentiation, Amgen Invests In Combos To Dominate KRAS G12C Field](#)" - Scrip, 6 Jun, 2022.)

(Also see "[BMS Hopes Turning Point Buyout Will Fare Better Than Roche's Ignyta Acquisition](#)" - Scrip, 3 Jun, 2022.)

(Also see "[MS Market Snapshot: New Options Confront Commercial Reality Of A Crowded Space](#)" -

Scrip, 3 Jun, 2022.)

(Also see "[\*How Biogen's Aduhelm Bet Became A Commercial Bust\*](#)" - Scrip, 6 Jun, 2022.)

[Click here to explore this interactive content online](#) ✎